Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 12, 2013, Pages 6223-6235

  Quashie, Peter K ^a,b   Mesplède, Thibault ^a   Han, Ying Shan ^a   Veres, Tamar ^a   Osman, Nathan ^a   Hassounah, Said ^a,b   Sloan, Richard D ^a   Xu, Hong Tao ^a   Wainberg, Mark A ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; HUMAN IMMUNODEFICIENCY VIRUS 1 INTEGRASE; INTEGRASE; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIVIRAL RESISTANCE; ARTICLE; CHEMICAL ANALYSIS; COMPETITIVE INHIBITION; CROSS RESISTANCE; DNA BINDING; DNA STRAND; ENZYME ACTIVE SITE; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; LONG TERMINAL REPEAT; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RNA PROCESSING; SITE DIRECTED MUTAGENESIS; SPUMA VIRUS;

DRUG RESISTANCE, VIRAL; ENZYME ACTIVATION; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; MUTAGENESIS, SITE-DIRECTED; MUTATION;

EID: 84887463456     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01835-13     Document Type: Article

References (58)

1. Bushman FD, Fujiwara T, Craigie R. 1990. Retroviral DNA integration directed by HIV integration protein in vitro. Science 249:1555-1558.
2. Pauza CD. 1990. Two bases are deleted from the termini of HIV-1 linear DNA during integrative recombination. Virology 179:886-889.
3. Lewinski MK, Bisgrove D, Shinn P, Chen H, Hoffmann C, Hannenhalli S, Verdin E, Berry CC, Ecker JR, Bushman FD. 2005. Genome-wide analysis of chromosomal features repressing human immunodeficiency virus transcription. J. Virol. 79:6610-6619.
4. Kulkosky J, Skalka AM. 1990. HIV DNA integration: observations and interferences. J. Acquir. Immune Defic. Syndr. 3:839-851.
5. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. 2000. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
6. FDA. 12 October 2007, posting date. FDA approval of Isentress (raltegravir). FDA, Silver Spring, MD.
7. Temesgen Z. 2012. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection. Drugs Today (Barc) 48:765-771.
8. Quashie PK, Sloan RD, Wainberg MA. 2012. Novel therapeutic strategies targeting HIV integrase.BMCMed. 10:34. doi:10.1186/1741-7015-10-34.
9. Hazuda DJ. 2010. Resistance to inhibitors of the human immunodeficiency virus type 1 integration. Braz. J. Infect. Dis. 14:513-518.
10. -1989. Oral candidosis in HIV infection. Lancet ii:1491-1492.
11. Mesplède T, Quashie PK, Wainberg MA. 2012. Resistance to HIV integrase inhibitors. Curr. Opin. HIV AIDS 7:401-408.
12. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. 2011. HIV-1 integrase inhibitor resistance and its clinical implications. J. Infect. Dis. 203:1204-1214.
13. Van Wesenbeeck L, Rondelez E, Feyaerts M, Verheyen A, Van der Borght K, Smits V, Cleybergh C, De Wolf H, Van Baelen K, Stuyver LJ. 2011. Cross-resistance profile determination of two second-generation HIV-1 integrase inhibitors using a panel of recombinant viruses derived from raltegravir-treated clinical isolates. Antimicrob. Agents Chemother. 55:321-325.
14. Quashie PK, Mesplede T, Wainberg MA. 2013. Evolution of HIV integrase resistance mutations. Curr. Opin. Infect. Dis. 26:43-49.
15. Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi- Miki S, Taishi T, Kawasuji T, Johns BA, Underwood MR, Garvey EP, Sato A, Fujiwara T. 2011. In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob. Agents Chemother. 55:813-821.
16. O'Neal R. 2011. Dolutegravir: a new integrase inhibitor in development. BETA 23:10-12.
17. Johnson BC, Métifiot M, Pommier Y, Hughes SH. 2012. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob. Agents Chemother. 56:411-419.
18. Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I, Peppercorn A, Everts S, Piscitelli S, Flexner C. 2013. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J. Acquir. Immune Defic. Syndr. 62:21-27.
19. Fantauzzi A, Turriziani O, Mezzaroma I. 2013. Potential benefit of dolutegravir once daily: efficacy and safety. HIV AIDS (Auckl) 5:29-40.
20. Waters LJ, Barber TJ. 2013. Dolutegravir for treatment of HIV: SPRING forwards? Lancet 381:705-706.
21. Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S. 2013. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 381: 735-743.
22. Eron JJ, Clotet B, Durant J, Katlama C, Kumar P, Lazzarin A, Poizot-Martin I, Richmond G, Soriano V, Ait-Khaled M, Fujiwara T, Huang J, Min S, Vavro C, Yeo J. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J. Infect. Dis. 207:740-748.
23. Wainberg MA, Quashie PK, Mesplede T. 2012. Dolutegravir HIV integrase inhibitor treatment of HIV infection. Drug Future 37:697-707. doi: 10.1358/dof.2012.37.10.1855759.
24. Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL, Broderick T, Sigethy S, Seki T, Kobayashi M, Underwood MR. 2011. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob. Agents Chemother. 55:4552-4559.
25. Vavro C, Hasan S, Madsen H, Horton J, DeAnda F, Martin-Carpenter L, Sato A, Cuffe R, Chen S, Underwood M, Nichols G. 2013. Prevalent polymorphisms in wild-type HIV-1 integrase are unlikely to engender drug resistance to dolutegravir (S/GSK1349572). Antimicrob. Agents Chemother. 57:1379-1384.
26. Bar-Magen T, Sloan RD, Donahue DA, Kuhl BD, Zabeida A, Xu H, Oliveira M, Hazuda DJ, Wainberg MA. 2010. Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J. Virol. 84:9210-9216.
27. Malet I, Fourati S, Charpentier C, Morand-Joubert L, Armenia D, Wirden M, Sayon S, Van Houtte M, Ceccherini-Silberstein F, Brun-Vézinet F, Perno CF, Descamps D, Capt A, Calvez V, Marcelin AG. 19 September 2011. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02-AG HIV-1 subtype. J. Antimicrob. Chemother. [Epub ahead of print.] doi:10.1093/jac/ dkr389.
28. Kobayashi M, Nakahara K, Seki T, Miki S, Kawauchi S, Suyama A, Wakasa-Morimoto C, Kodama M, Endoh T, Oosugi E, Matsushita Y, Murai H, Fujishita T, Yoshinaga T, Garvey E, Foster S, Underwood M, Johns B, Sato A, Fujiwara T. 2008. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants. Antiviral Res. 80:213-222.
29. Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second- generation integrase strand transfer inhibitor dolutegravir. J. Virol. 86:2696-2705.
30. Mesplède T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22. doi:10.1186/1742-4690-10-22.
31. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. 2010. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464:232-236.
32. Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. 2010. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS 24:2171-2179.
33. Bar-Magen T, Sloan RD, Faltenbacher VH, Donahue DA, Kuhl BD, Oliveira M, Xu H, Wainberg MA. 2009. Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes. Retrovirology 6:103. doi:10.1186/1742-4690-6-103.
34. Han YS, Xiao WL, Quashie PK, Mesplede T, Xu H, Deprez E, Delelis O, Pu JX, Sun HD, Wainberg MA. 2013. Development of a fluorescencebased HIV-1 integrase DNA binding assay for identification of novel HIV-1 integrase inhibitors. Antiviral Res. 98:441-448.
35. Han YS, Quashie P, Mesplede T, Xu H, Mekhssian K, Fenwick C, Wainberg MA. 2012. A high-throughput assay for HIV-1 integrase 3=- processing activity using time-resolved fluorescence. J. Virol. Methods 184:34-40.
36. Cleland WW. 1989. The kinetics of enzyme-catalyzed reactions with two or more substrates or products. I. Nomenclature and rate equations. 1963. Biochim. Biophys. Acta 1000:213-220.
37. Cleland WW. 1967. Enzyme kinetics. Annu. Rev. Biochem. 36:77-112.
38. Zhang Y. 2009. I-TASSER: fully automated protein structure prediction in CASP8. Proteins 77(Suppl 9):100-113.
39. Bhuyan MS, Gao X. 2011. A protein-dependent side-chain rotamer library. BMC Bioinformatics 12(Suppl 14):S10.
40. Bower MJ, Cohen FE, Dunbrack RL, Jr. 1997. Prediction of protein side-chain rotamers from a backbone-dependent rotamer library: a new homology modeling tool. J. Mol. Biol. 267:1268-1282.
41. Hare S, Smith SJ, Métifiot M, Jaxa-Chamiec A, Pommier Y, Hughes SH, Cherepanov P. 2011. Structural and functional analyses of the secondgeneration integrase strand transfer inhibitor dolutegravir (S/ GSK1349572). Mol. Pharmacol. 80:565-572.
42. Hare S, Maertens GN, Cherepanov P. 2012. 3=-Processing and strand transfer catalysed by retroviral integrase in crystallo. EMBO J. 31:3020-3028.
43. Jenkins TM, Engelman A, Ghirlando R, Craigie R. 1996. A soluble active mutant of HIV-1 integrase: involvement of both the core and carboxyl-terminal domains in multimerization. J. Biol. Chem. 271: 7712-7718.
44. Jenkins TM, Hickman AB, Dyda F, Ghirlando R, Davies DR, Craigie R. 1995. Catalytic domain of human immunodeficiency virus type 1 integrase: identification of a soluble mutant by systematic replacement of hydrophobic residues. Proc. Natl. Acad. Sci. U. S. A. 92:6057-6061.
45. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. 1994. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266:1981-1986.
46. Cleland WW. 1975. Partition analysis and the concept of net rate constants as tools in enzyme kinetics. Biochemistry 14:3220-3224.
47. Smolov M, Gottikh M, Tashlitskii V, Korolev S, Demidyuk I, Brochon JC, Mouscadet JF, Deprez E. 2006. Kinetic study of the HIV-1 DNA 3=-end processing. FEBS J. 273:1137-1151.
48. Deprez E, Barbe S, Kolaski M, Leh H, Zouhiri F, Auclair C, Brochon JC, Le Bret M, Mouscadet JF. 2004. Mechanism of HIV-1 integrase inhibition by styrylquinoline derivatives in vitro. Mol. Pharmacol. 65: 85-98.
49. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR. 1999. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc. Natl. Acad. Sci. U. S. A. 96:13040-13043.
50. Parrill AL. 2003. HIV-1 integrase inhibition: binding sites, structure activity relationships and future perspectives. Curr. Med. Chem. 10:1811-1824.
51. Xu D, Zhang J, Roy A, Zhang Y. 2011. Automated protein structure modeling in CASP9 by I-TASSER pipeline combined with QUARK-based ab initio folding and FG-MD-based structure refinement. Proteins 79(Suppl 10):147-160.
52. Quashie PK, Mesplede T, Wainberg MA. 2013. HIV drug resistance and the advent of integrase inhibitors. Curr. Infect. Dis. Rep. 15:85-100.
53. Wainberg MA, Mesplede T, Quashie PK. 2012. The development of novel HIV integrase inhibitors and the problem of drug resistance. Curr. Opin. Virol. 2:656-662.
54. Cherepanov P, Maertens GN, Hare S. 2011. Structural insights into the retroviral DNA integration apparatus. Curr. Opin. Struct. Biol. 21:249-256.
55. Li X, Krishnan L, Cherepanov P, Engelman A. 2011. Structural biology of retroviral DNA integration. Virology 411:194-205.
56. Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR, Pommier Y. 2002. Structural determinants for HIV-1 integrase inhibition by beta-diketo acids. J. Biol. Chem. 277:12596-12603.
57. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. 2010. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc. Natl. Acad. Sci. U. S. A. 107: 20057-20062.
58. Nowotny M, Gaidamakov SA, Crouch RJ, Yang W. 2005. Crystal structures of RNaseHbound to an RNA/DNA hybrid: substrate specificity and metal-dependent catalysis. Cell 121:1005-1016.